Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Autoimmune Disorders

  Free Subscription


19.03.2018

2 Acta Neurol Scand
1 Ann Neurol
3 BMC Neurol
7 Diabet Med
4 Diabetes Res Clin Pract
2 Intern Med
1 J Autoimmun
3 J Immunol
4 J Neuroimmunol
2 J Neurol
19 Mult Scler
7 N Engl J Med
3 Neurology
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Acta Neurol Scand

  1. HEYDARPOUR P, Manouchehrinia A, Beiki O, Mousavi SE, et al
    Smoking and worsening disability in multiple sclerosis: A meta-analysis.
    Acta Neurol Scand. 2018 Mar 15. doi: 10.1111/ane.12916.
    PubMed     Text format     Abstract available

  2. VISTBAKKA J, Sumelahti ML, Lehtimaki T, Elovaara I, et al
    Evaluation of serum miR-191-5p, miR-24-3p, miR-128-3p, and miR-376c-3 in multiple sclerosis patients.
    Acta Neurol Scand. 2018 Mar 12. doi: 10.1111/ane.12921.
    PubMed     Text format     Abstract available


    Ann Neurol

  3. ANTEL J
    The reality of "ghosts" in authorship of clinical trials in multiple sclerosis.
    Ann Neurol. 2018 Mar 13. doi: 10.1002/ana.25199.
    PubMed     Text format    


    BMC Neurol

  4. STOPPE M, Busch M, Krizek L, Then Bergh F, et al
    Outcome of MS relapses in the era of disease-modifying therapy.
    BMC Neurol. 2017;17:151.
    PubMed     Text format     Abstract available

  5. THAWANI SP, Brannagan TH, Lebwohl B, Green PHR, et al
    Celiac disease and risk of myasthenia gravis - nationwide population-based study.
    BMC Neurol. 2018;18:28.
    PubMed     Text format     Abstract available

  6. ALROUGHANI R, Boyko A
    Pediatric multiple sclerosis: a review.
    BMC Neurol. 2018;18:27.
    PubMed     Text format     Abstract available


    Diabet Med

  7. O'HARA MC, Hynes L, O'Donnell M, Nery N, et al
    A systematic review of interventions to improve outcomes for young adults with Type 1 diabetes.
    Diabet Med. 2016 Oct 20. doi: 10.1111/dme.13276.
    PubMed     Text format     Abstract available

  8. NIEUWESTEEG A, Hartman E, Emons W, van Bakel H, et al
    Paediatric parenting stress in fathers and mothers of young children with Type 1 diabetes: a longitudinal study.
    Diabet Med. 2016 Dec 14. doi: 10.1111/dme.13300.
    PubMed     Text format     Abstract available

  9. CLARKE AB, Daneman D, Curtis JR, Mahmud FH, et al
    Impact of neighbourhood-level inequity on paediatric diabetes care.
    Diabet Med. 2017 Feb 6. doi: 10.1111/dme.13326.
    PubMed     Text format     Abstract available

  10. HARRIS SM, Shah P, Mulnier H, Healey A, et al
    Factors influencing attendance at structured education for Type 1 diabetes in south London.
    Diabet Med. 2017 Feb 14. doi: 10.1111/dme.13333.
    PubMed     Text format     Abstract available

  11. CAI RA, Holt RI, Casdagli L, Viner RM, et al
    Development of an acceptable and feasible self-management group for children, young people and families living with Type 1 diabetes.
    Diabet Med. 2017 Feb 22. doi: 10.1111/dme.13341.
    PubMed     Text format     Abstract available

  12. EGAN AM, Carmody L, Kirwan B, Dunne FP, et al
    Care of women with diabetes before, during and after pregnancy: time for a new approach?
    Diabet Med. 2017 Feb 22. doi: 10.1111/dme.13342.
    PubMed     Text format     Abstract available

  13. PATERSON MA, Smart CE, Lopez PE, Howley P, et al
    Increasing the protein quantity in a meal results in dose-dependent effects on postprandial glucose levels in individuals with Type 1 diabetes mellitus.
    Diabet Med. 2017 Mar 3. doi: 10.1111/dme.13347.
    PubMed     Text format     Abstract available


    Diabetes Res Clin Pract

  14. KLONOFF DC, Ahn D, Drincic A
    Continuous glucose monitoring: A review of the technology and clinical use.
    Diabetes Res Clin Pract. 2017;133:178-192.
    PubMed     Text format     Abstract available

  15. YUE Y, Meng K, Pu Y, Zhang X, et al
    Transforming growth factor beta (TGF-beta) mediates cardiac fibrosis and induces diabetic cardiomyopathy.
    Diabetes Res Clin Pract. 2017;133:124-130.
    PubMed     Text format     Abstract available

  16. ALMAHFOODH D, Alabbood M, Alali A, Mansour A, et al
    Epidemiology of type 1 diabetes mellitus in Basrah, Southern Iraq: A retrospective study.
    Diabetes Res Clin Pract. 2017;133:104-108.
    PubMed     Text format     Abstract available

  17. RODACKI M, Carvalho RM, Zajdenverg L
    The potential effect of ultra-long insulin degludec on glycemic variability.
    Diabetes Res Clin Pract. 2017;133:92-103.
    PubMed     Text format     Abstract available


    Intern Med

  18. KUDO F, Watanabe Y, Iwai Y, Miwa C, et al
    A Case of Advanced Lung Adenocarcinoma with Nvolumab-associated Dermatomyositis.
    Intern Med. 2018 Mar 9. doi: 10.2169/internalmedicine.9381.
    PubMed     Text format     Abstract available

  19. SUK LEE Y, Kim NH, Hyuk Son J, Wook Kim J, et al
    Type 2 Autoimmune Pancreatitis with Crohn's Disease.
    Intern Med. 2018 Mar 9. doi: 10.2169/internalmedicine.0213.
    PubMed     Text format     Abstract available


    J Autoimmun

  20. ZHAO K, Du J, Peng Y, Li P, et al
    LINE1 contributes to autoimmunity through both RIG-I- and MDA5-mediated RNA sensing pathways.
    J Autoimmun. 2018 Mar 7. pii: S0896-8411(17)30780.
    PubMed     Text format     Abstract available


    J Immunol

  21. SPIRIG R, Campbell IK, Koernig S, Chen CG, et al
    rIgG1 Fc Hexamer Inhibits Antibody-Mediated Autoimmune Disease via Effects on Complement and FcgammaRs.
    J Immunol. 2018 Mar 12. pii: jimmunol.1701171. doi: 10.4049/jimmunol.1701171.
    PubMed     Text format     Abstract available

  22. O'DONNELL JA, Lehman J, Roderick JE, Martinez-Marin D, et al
    Correction: Dendritic Cell RIPK1 Maintains Immune Homeostasis by Preventing Inflammation and Autoimmunity.
    J Immunol. 2018 Mar 12. pii: jimmunol.1800240. doi: 10.4049/jimmunol.1800240.
    PubMed     Text format    

  23. SAGE PT, Schildberg FA, Sobel RA, Kuchroo VK, et al
    Dendritic Cell PD-L1 Limits Autoimmunity and Follicular T Cell Differentiation and Function.
    J Immunol. 2018 Mar 12. pii: jimmunol.1701231. doi: 10.4049/jimmunol.1701231.
    PubMed     Text format     Abstract available


    J Neuroimmunol

  24. BARBOUR M, Wood R, Hridi SU, Wilson C, et al
    The therapeutic effect of anti-CD52 treatment in murine experimental autoimmune encephalomyelitis is associated with altered IL-33 and ST2 expression levels.
    J Neuroimmunol. 2018 Feb 24. pii: S0165-5728(17)30457.
    PubMed     Text format     Abstract available

  25. ASHTARI F, Esmaeil N, Mansourian M, Poursafa P, et al
    An 8-year study of people with multiple sclerosis in Isfahan, Iran: Association between environmental air pollutants and severity of disease.
    J Neuroimmunol. 2018 Mar 2. pii: S0165-5728(18)30019.
    PubMed     Text format     Abstract available

  26. SMITH PA, Schmid C, Zurbruegg S, Jivkov M, et al
    Fingolimod inhibits brain atrophy and promotes brain-derived neurotrophic factor in an animal model of multiple sclerosis.
    J Neuroimmunol. 2018 Mar 3. pii: S0165-5728(17)30519.
    PubMed     Text format     Abstract available

  27. ALLENDER E, Deol H, Schram S, Maheras KJ, et al
    Neuregulin1 modulation of experimental autoimmune encephalomyelitis (EAE).
    J Neuroimmunol. 2018 Mar 10. pii: S0165-5728(17)30466.
    PubMed     Text format     Abstract available


    J Neurol

  28. AOYAMA S, Mori M, Uzawa A, Uchida T, et al
    Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration.
    J Neurol. 2018 Mar 12. pii: 10.1007/s00415-018-8813.
    PubMed     Text format     Abstract available

  29. DEVONSHIRE V, Phillips R, Wass H, Da Roza G, et al
    Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations.
    J Neurol. 2018 Mar 10. pii: 10.1007/s00415-018-8822.
    PubMed     Text format     Abstract available


    Mult Scler

  30. HAAS J, Schneider K, Schwarz A, Korporal-Kuhnke M, et al
    Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
    Mult Scler. 2017;23:114-118.
    PubMed     Text format     Abstract available

  31. KALINCIK T, Sormani MP
    Reporting treatment outcomes in observational data: A fine balance.
    Mult Scler. 2017;23:21-22.
    PubMed     Text format     Abstract available

  32. SORMANI MP
    Subgroup analysis in MS trials.
    Mult Scler. 2017;23:34-35.
    PubMed     Text format     Abstract available

  33. SILLER N, Kuhle J, Muthuraman M, Barro C, et al
    Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518765666. doi: 10.1177/1352458518765666.
    PubMed     Text format     Abstract available

  34. SOWA P, Harbo HF, White NS, Celius EG, et al
    Restriction spectrum imaging of white matter and its relation to neurological disability in multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518765671. doi: 10.1177/1352458518765671.
    PubMed     Text format     Abstract available

  35. CORTI L, Ayrignac X, Carra Dalliere C, Charif M, et al
    Late activity rebound in non-active multiple sclerosis: A rare event.
    Mult Scler. 2018 Mar 1:1352458518765670. doi: 10.1177/1352458518765670.
    PubMed     Text format    

  36. CASTELLI L, Prosperini L, Pozzilli C
    Balance worsening associated with nabiximols in multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518765649. doi: 10.1177/1352458518765649.
    PubMed     Text format     Abstract available

  37. GRAETZ C, Groger A, Luessi F, Salmen A, et al
    Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518763541. doi: 10.1177/1352458518763541.
    PubMed     Text format     Abstract available

  38. BURTON JM, Eliasziw M, Trufyn J, Tung C, et al
    A prospective cohort study of vitamin D in optic neuritis recovery.
    Mult Scler. 2017;23:82-93.
    PubMed     Text format     Abstract available

  39. LAROCHELLE C, Metz I, Lecuyer MA, Terouz S, et al
    Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal.
    Mult Scler. 2017;23:72-81.
    PubMed     Text format     Abstract available

  40. GIRARD B, Bonnemains C, Schmitt E, Raffo E, et al
    Biotinidase deficiency mimicking neuromyelitis optica beginning at the age of 4: A treatable disease.
    Mult Scler. 2017;23:119-122.
    PubMed     Text format     Abstract available

  41. SORMANI MP
    Prognostic factors versus markers of response to treatment versus surrogate endpoints: Three different concepts.
    Mult Scler. 2017;23:378-381.
    PubMed     Text format     Abstract available

  42. BACCHETTA F, Mathias A, Schluep M, Du Pasquier R, et al
    Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.
    Mult Scler. 2017;23:300-303.
    PubMed     Text format     Abstract available

  43. HUH SY, Kim SH, Hyun JW, Jeong IH, et al
    Short segment myelitis as a first manifestation of neuromyelitis optica spectrum disorders.
    Mult Scler. 2017;23:413-419.
    PubMed     Text format     Abstract available

  44. HAMID SH, Elsone L, Mutch K, Solomon T, et al
    The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates.
    Mult Scler. 2017;23:228-233.
    PubMed     Text format     Abstract available

  45. DECARD BF, Thone J, Haghikia A, Bornke C, et al
    Listeria rhombencephalitis mimicking a demyelinating event in an immunocompetent young patient.
    Mult Scler. 2017;23:123-125.
    PubMed     Text format     Abstract available

  46. GRAVES JS, Chohan H, Cedars B, Arnow S, et al
    Sex differences and subclinical retinal injury in pediatric-onset MS.
    Mult Scler. 2017;23:447-455.
    PubMed     Text format     Abstract available

  47. SORMANI MP, Bruzzi P
    Estimating a treatment effect: Choosing between relative and absolute measures.
    Mult Scler. 2017;23:197-200.
    PubMed     Text format     Abstract available

  48. SORMANI MP, Muraro PA, Saccardi R, Mancardi G, et al
    NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs.
    Mult Scler. 2017;23:201-204.
    PubMed     Text format     Abstract available


    N Engl J Med

  49. CASEY JD, Englert JA, Katz JT, Miller AL, et al
    An Unexpected Expectoration.
    N Engl J Med. 2018;378:853-858.
    PubMed     Text format    

  50. DALMAU J, Graus F
    Antibody-Mediated Encephalitis.
    N Engl J Med. 2018;378:840-851.
    PubMed     Text format    


  51. Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes.
    N Engl J Med. 2018;378:966-968.
    PubMed     Text format    

  52. GOGTAY NJ, Bose D, Thatte UM
    Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes.
    N Engl J Med. 2018;378:966.
    PubMed     Text format    

  53. CONTE C, Secchi A, Napoli N
    Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes.
    N Engl J Med. 2018;378:966.
    PubMed     Text format    

  54. DOUMAS M, Imprialos KP, Stavropoulos K
    Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes.
    N Engl J Med. 2018;378:967.
    PubMed     Text format    

  55. KHOO TK, Olson KM
    Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes.
    N Engl J Med. 2018;378:967.
    PubMed     Text format    


    Neurology

  56. GAETANO L, Haring DA, Radue EW, Mueller-Lenke N, et al
    Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis.
    Neurology. 2018 Mar 14. pii: WNL.0000000000005292.
    PubMed     Text format     Abstract available

  57. SCHOONHEIM MM, Ciccarelli O
    The value of including thalamic atrophy as a clinical trial endpoint in multiple sclerosis.
    Neurology. 2018 Mar 14. pii: WNL.0000000000005279.
    PubMed     Text format    

  58. MCKAY KA, Tremlett H, Fisk JD, Zhang T, et al
    Psychiatric comorbidity is associated with disability progression in multiple sclerosis.
    Neurology. 2018 Mar 9. pii: WNL.0000000000005302.
    PubMed     Text format     Abstract available


    PLoS One

  59. HASSANI A, Corboy JR, Al-Salam S, Khan G, et al
    Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells.
    PLoS One. 2018;13:e0192109.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: